Skip to main content


Design of the first-in-class SARS-CoV-2 papain-like protease inhibitors with in vivo antiviral efficacy in a mouse model


Welcome Yvonne Wen, who joined us as a Research Assistant Professor!


We are glad to share our results of SARS-CoV-2 main protease drug resistant mutants on the World Health Organization meeting Scientific Strategies From Recent Outbreaks To Help Us Prepare For Pathogen X.


China approves first homegrown COVID antiviral


Bad news for Paxlovid? Coronavirus can find multiple ways to evade COVID-19 drug


Some Pre-existing Mutant Strains of the Virus Causing COVID-19 May Resist Paxlovid


Coronavirus hasn’t developed resistance to Paxlovid. How long can that last?

Coronavirus hasn’t developed resistance to Paxlovid. How long can that last?


新冠口服药对奥密克戎仍有效,但需警惕抗药性 (Paxlovid remains effective against Omicron variant, but be cautious)


Paxlovid update


Research at Ernest Mario School of Pharmacy finds that antiviral drug can treat coronavirus


How Omicron is Challenging China’s Grip on COVID-19


Our study of the SARS-CoV-2 Mpro mutant was highlighted in Rutgers Today!


Study joins search for variant-proof approach to SARS-CoV-2 treatment.


COVID-19 antiviral drugs (SciLine)

COVID-19 antiviral drugs

Pfizer: Partnerships and anti-infective efforts

Our paper on the rational design of non-covalent SARS-CoV-2 main protease inhibitors was published in
J. Med. Chem. The non-covalent Mpro inhibitors are highly selective against host cysteine proteases, while the canonical Mpro inhibitors such as GC376 were not selective and inhibited a number of host proteases. The most potent compound 23R occupies a new pocket in Mpro that has not been explored before.

In a following up study, we have shown that boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-NL63, and HCoV-229E in addition to SARS-CoV-2. More importantly, all four compounds also had potent antiviral activity against SARS-CoV-2 in TMPRSS2-expressing Caco2 cells. Check our recent publication in ACS Infect. Dis. 

Our paper entitled “The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor” was accepted by Emerging Microbes and Infections. In this study, we have shown the lactoferrin, a natural protein that is abundant in milk, inhibits multiple coronaviruses including SARS-CoV-2 by preventing the binding of the virus to the host heparan sulfate attachment factor.  Check this paper at

Our letter to the editor entitled “Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors” was accepted by
Proc. Natl. Acad. Sci. U S A. In this communication, we provided experimental evidence to invalidate the previous reported SARS-CoV-2 main protease inhibitor in this paper

Our Science Advances paper is online! Check it out!

Dr. Wang is honored to be elected as the editorial board member of the European Journal of Pharmaceutical Sciences, which he has reviewed more than 80 manuscripts so far! Check it out:

In this preprint we have shown that boceprevir, calpain inhibitors II and XII, and GC-376 not only inhibits SARS-CoV-2, but also SARS-CoV, MERS-CoV, and seasonal human coronaviruses HCoV-NL63, HCoV-229E, and HCoV-OC43.
Check out the news coverage of this study at News Medical Life Sciences.
Discovery of four SARS-CoV-2 Mpro inhibitors, boceprevir, calpain inhibitors II and XII and GC-376

Our manuscript entitled “Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L” was accepted by Science Advances. Thanks to our collaborators Dr. Yu Chen (USF), Dr. Michael Marty (UA), Dr. Yan Xiang (UTSA), Dr. Brett Hurst and Dr. Bart Tarbet (USU) for their contribution!